Discovery of novel biomarker candidates for liver Fibrosis in Hepatitis C patients: A preliminary study

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Gangadharan, Bevin ^a   Bapat, Manisha ^a   Rossa, Jan ^a   Antrobus, Robin ^a   Chittenden, David ^a   Kampa, Bettina ^a   Barnes, Eleanor ^b,c   Klenerman, Paul ^b   Dwek, Raymond A ^a   Zitzmann, Nicole ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN L1; BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C3D; LIPID TRANSFER INHIBITOR PROTEIN; TRANSCORTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; ISHAK FIBROSIS SCORE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PROTEIN BLOOD LEVEL; PROTEOMICS; SCORING SYSTEM; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGED; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CLUSTERIN; COMPLEMENT C3D; FEMALE; HEPATITIS C; HUMANS; LIPOPROTEINS, HDL; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TRANSCORTIN;

EID: 84862748336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039603     Document Type: Article

References (31)

1. Marcellin P, (1999) Hepatitis C: the clinical spectrum of the disease. J Hepatol 31: 9-16.
2. Bataller R, Brenner DA, (2005) Liver fibrosis. J Clin Invest 115: 209-218.
3. Cadranel JF, Mathurin P, (2002) Prothrombin index decrease: a useful and reliable marker of extensive fibrosis? Eur J Gastroenterol Hepatol 14: 1057-1059.
4. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075.
5. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, et al. (2003) Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 49: 450-454.
6. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713.
7. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, et al. (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47: 455-460.
8. Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, et al. (1997) Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 265: 21-31.
9. Zohrens G, Armbrust T, Meyer Zum Buschenfelde KH, Ramadori G, (1994) Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection. Dig Dis Sci 39: 2007-2013.
10. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, et al. (2005) Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51: 1867-1873.
11. Poordad FF, (2004) FIBROSpect II: a potential noninvasive test to assess hepatic fibrosis. Expert Rev Mol Diagn 4: 593-597.
12. Pinzani M, (2010) The ELF panel: a new crystal ball in hepatology? Gut 59: 1165-1167.
13. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N, (2007) Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 53: 1792-1799.
14. White IR, Patel K, Symonds WT, Dev A, Griffin P, et al. (2007) Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med 5: 33.
15. Gangadharan B, Antrobus R, Chittenden D, Rossa J, Bapat M, et al. (2011) New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. J Proteome Res 10: 2643-2650.
16. Gangadharan B, Zitzmann N, (2011) Two dimensional gel electrophoresis using narrow pH 3-5.6 immobilised pH gradient strips identifies potential novel disease biomarkers in plasma or serum. Nature Protocol Exchange doi: 10.1038/protex.2011.261.
17. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
18. Matheson LA, Duong TT, Rosenberg AM, Yeung RS, (2008) Assessment of sample collection and storage methods for multicenter immunologic research in children. J Immunol Methods 339: 82-89.
19. Garcia A, Prabhakar S, Hughan S, Anderson TW, Brock CJ, et al. (2004) Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood 103: 2088-2095.
20. Pardo M, Garcia A, Antrobus R, Blanco MJ, Dwek RA, et al. (2007) Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J Proteome Res 6: 2802-2811.
21. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H, (2008) Proteomics in liver fibrosis is more than meets the eye. Eur J Gastroenterol Hepatol 20: 450-464.
22. Lagor WR, Brown RJ, Toh SA, Millar JS, Fuki IV, et al. (2009) Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Arterioscler Thromb Vasc Biol 29: 40-46.
23. Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, et al. (1993) Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology 18: 103-110.
24. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, et al. (2005) JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 5: 30.
25. Huang H, Sun F, Owen DM, Li W, Chen Y, et al. (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 104: 5848-5853.
26. Aigelsreiter A, Janig E, Sostaric J, Pichler M, Unterthor D, et al. (2009) Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis. Histopathology 54: 561-570.
27. Saldova R, Wormald MR, Dwek RA, Rudd PM, (2008) Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 25: 219-232.
28. He Z, Aristoteli LP, Kritharides L, Garner B, (2006) HPLC analysis of discrete haptoglobin isoform N-linked oligosaccharides following 2D-PAGE isolation. Biochem Biophys Res Commun 343: 496-503.
29. Sarrats A, Saldova R, Pla E, Fort E, Harvey DJ, et al. (2010) Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl 4: 432-448.
30. Tolosano E, Fagoonee S, Hirsch E, Berger FG, Baumann H, et al. (2002) Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 100: 4201-4208.
31. Parkes J, Guha IN, Roderick P, Harris S, Cross R, et al. (2010) Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat.